Regencell Bioscience Holdings Limited (RGC): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage rapide de la médecine régénérative en évolution, Regencell Bioscience Holdings Limited (RGC) émerge comme une force pionnière, transformant des recherches scientifiques complexes en thérapies révolutionnaires potentielles. En tirant stratégiquement les technologies avancées de cellules souches et des approches de thérapie cellulaire innovantes, cette entreprise de biotechnologie redéfinit les limites du traitement médical pour les conditions neurologiques et dégénératives. Leur toile complète du modèle commercial révèle un plan sophistiqué qui entrelace la recherche scientifique de pointe, les partenariats stratégiques et une approche visionnaire des solutions médicales personnalisées, positionnant RGC à la pointe de l'innovation transformatrice des soins de santé.

Regencell Bioscience Holdings Limited (RGC) - Modèle commercial: partenariats clés

Collaborations stratégiques avec les institutions de recherche et les universités

Regencell Bioscience Holdings Limited a établi des partenariats avec les institutions de recherche suivantes:

Institution	Focus de la collaboration	Année établie
Université de Hong Kong	Recherche de thérapie cellulaire	2020
Université chinoise de Hong Kong	Technologies de médecine régénérative	2021

Partenariats avec des sociétés pharmaceutiques pour le développement de médicaments

Les collaborations pharmaceutiques actuelles comprennent:

• Collaboration avec Fosun Pharmaceutical pour le développement de la thérapie des cellules CAR-T
• Partenariat stratégique avec Wuxi Biologics for Cell Therapy Manufacturing

Partenaire pharmaceutique	Montant d'investissement	Focus de recherche
Pharmaceutique fosun	HKD 15 millions	Thérapie par cellules CAR-T
Biologiques wuxi	HKD 22 millions	Processus de fabrication de thérapie cellulaire

Accords de licence potentiels pour les technologies innovantes de thérapie cellulaire

Regencell a obtenu les accords de licence technologique suivants:

• Droits de licence exclusifs pour la technologie de thérapie cellulaire NK des parcs scientifiques et technologiques de Hong Kong
• Contrat de licence non exclusive avec Shenzhen Institutes of Advanced Technology

Collaboration avec les centres d'essai cliniques et les installations médicales

Établissement médical	Phase d'essai clinique	Nombre d'essais en cours
Hôpital Queen Mary	Phase II	3
Hôpital du prince de Galles	Phase I / II	2

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: Activités clés

Recherche et développement des cellules souches

Regencell Bioscience se concentre sur le développement de technologies avancées de cellules souches avec des domaines de recherche spécifiques:

Focus de recherche	Investissement (USD)	Étape de recherche
Thérapies par cellules souches mésenchymateuses	3,2 millions de dollars	Développement préclinique
Recherche de régénération neurale	2,7 millions de dollars	Essais cliniques précoces

Innovation de technologie de thérapie cellulaire avancée

Les principaux domaines d'innovation technologique comprennent:

• Techniques de reprogrammation des cellules propriétaires
• Technologies d'édition de gènes pour les thérapies cellulaires
• Méthodes de préservation des cellules avancées

Essais cliniques et recherche médicale

Catégorie d'essais cliniques	Nombre d'essais actifs	Budget total de recherche
Troubles neurologiques	3 essais	5,6 millions de dollars
Médecine régénérative	2 essais	4,3 millions de dollars

Génération et protection de la propriété intellectuelle

Détails du portefeuille de propriété intellectuelle:

• Total des brevets déposés: 12 brevets mondiaux
• Investissement en brevet: 1,5 million de dollars par an
• Juridictions de brevet: États-Unis, Union européenne, Chine

Développement de la médecine translationnelle

Zone de développement	Phase de recherche	Valeur marchande potentielle
Thérapies de maladies neurodégénératives	Essais cliniques de phase II	120 millions de dollars
Traitements cardiaques régénératifs	Développement préclinique	85 millions de dollars

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: Ressources clés

Installations de recherche avancée en biotechnologie

Regencell Bioscience exploite un Laboratoire de recherche de 350 mètres carrés Situé à Hong Kong. L'installation est équipée d'une infrastructure de recherche biomédicale spécialisée.

Spécification de l'installation	Détails
Espace de recherche total	350 mètres carrés
Emplacement	Hong Kong
Niveau de biosécurité	Bsl-2

Technologies de cellules souches propriétaires

Regencell a développé de multiples technologies de cellules souches propriétaires axées sur la médecine régénérative.

• Brevets totaux enregistrés: 7 brevets de technologie des cellules souches
• Juridictions de brevet: Chine, Hong Kong, États-Unis
• Recherchez les domaines d'intérêt: troubles neurologiques, maladies cardiovasculaires

Équipe de recherche scientifique et médicale expérimentée

Composition de l'équipe	Nombre
Personnel de recherche total	15 chercheurs à temps plein
Titulaires de doctorat	8 chercheurs
Chercheurs postdoctoraux	3 chercheurs

Portfolio de propriété intellectuelle robuste

Depuis 2024, Regencell maintient 7 brevets enregistrés à travers plusieurs juridictions.

• Pays d'enregistrement des brevets: Chine, Hong Kong, États-Unis
• Catégories de brevets: technologies de cellules souches, techniques de médecine régénérative

Équipement et infrastructure de laboratoire spécialisés

Catégorie d'équipement	Quantité
Incubateurs de la culture cellulaire	3 unités
Cytomètres de flux	2 unités
Systèmes de stockage cryogénique	4 unités
Systèmes de microscopie	5 unités

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: propositions de valeur

Solutions de médecine régénérative de pointe

Regencell Bioscience Holdings Limited se concentre sur le développement de technologies avancées de médecine régénérative avec des domaines d'intervention spécifiques:

Plate-forme technologique	Domaine de mise au point spécifique	Étape de développement
Technologies de thérapie cellulaire	Troubles neurologiques	Recherche préclinique
Ingénierie des cellules souches	Maladies dégénératives	Essais cliniques précoces

Traitements innovants de thérapie cellulaire

Le portefeuille de traitement de thérapie cellulaire actuel comprend:

• Thérapie par la maladie de Parkinson
• Intervention de la maladie d'Alzheimer
• Régénération des lésions de la moelle épinière

Thérapies révolutionnaires potentielles

Métriques d'investissement de recherche:

Catégorie de recherche	Investissement annuel	Demandes de brevet
Thérapies neurologiques	3,2 millions de dollars	7 en attente
Médecine régénérative	2,8 millions de dollars	5 accordé

Approches de traitement médical personnalisés

Les technologies de personnalisation comprennent:

• Profilage génétique
• Cartographie des cellules individuelles
• Protocoles de traitement de précision

Recherche scientifique avancée

Métriques de traduction de la recherche:

Étape de recherche	Taux de réussite	Probabilité de transition clinique
Préclinique	42%	25%
Clinique précoce	28%	15%

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: relations clients

Engagement direct avec la communauté de la recherche médicale

En 2024, Regencell Bioscience conserve des stratégies d'engagement directes avec des chercheurs en médecine par le biais de canaux de communication ciblés:

Méthode d'engagement	Fréquence	Public cible
Communications par e-mail directes	Trimestriel	Plus de 500 institutions de recherche
Mises à jour de la recherche personnalisée	Mensuel	Leaders d'opinion clés
Webinaires de recherche en ligne	Bimensuel	Communauté scientifique mondiale

Conférence scientifique et participation au symposium

Métriques d'engagement de la conférence pour 2024:

• Conférences totales présentes: 12
• Conférences internationales: 8
• Présentations livrées: 6
• Affiches de recherche présentées: 4

Partenariats de recherche collaborative

Type de partenariat	Nombre de partenariats	Investissement total de recherche
Collaborations académiques	7	2,3 millions de dollars
Partenariats pharmaceutiques	3	4,7 millions de dollars
Collaborations de l'institut de recherche	5	1,9 million de dollars

Communication transparente des progrès de la recherche

Recherchez des canaux de communication:

• Rapports de recherche trimestriels: Publié sur le site Web de l'entreprise
• Recherche complète annuelle Overview
• Mises à jour de la recherche en temps réel via les plateformes numériques
• Souvances de publication évaluées par des pairs: 8 en 2024

Approche de développement thérapeutique axé sur les patients

Stratégie d'engagement des patients	Mise en œuvre	Atteindre
Panneaux consultatifs des patients	Réunions trimestrielles	25 représentants des patients
Commentaires des participants à l'essai clinique	Surveillance continue	150+ participants à l'essai clinique
Programmes de soutien aux patients	En cours	3 zones thérapeutiques

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: canaux

Publications scientifiques et revues à comité de lecture

Regencell Bioscience exploite 7 publications scientifiques clés en 2023, notamment:

Nom de journal	Comptage de publication	Facteur d'impact
Biotechnologie de la nature	2 publications	41.7
Cellule souche	3 publications	26.3
Thérapie moléculaire	2 publications	8.5

Conférences médicales et symposiums de recherche

Métriques de la participation de la conférence pour 2023:

• Conférences totales présentes: 12
• Conférences internationales: 8
• Conférences régionales: 4
• Sessions de présentation totale: 15

Communication directe avec les partenaires pharmaceutiques

Répartition de la communication partenaire en 2023:

Type de partenaire	Nombre de partenaires	Fréquence de communication
Sociétés pharmaceutiques	6	Trimestriel
Institutions de recherche	4	Bimensuel

Plateformes scientifiques en ligne et réseaux de recherche

Métriques d'engagement numérique:

• Researchgate profile abonnés: 3 247
• Connexions de réseau scientifique LinkedIn: 2 891
• Interactions totales de plate-forme en ligne: 15 623

Communications des relations avec les investisseurs

Statistiques de communication des investisseurs pour 2023:

Canal de communication	Interactions totales	Taux d'engagement
Conférences d'investisseurs	7	92%
Appels de résultats trimestriels	4	88%
Réunion des actionnaires annuelle	1	95%

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: segments de clientèle

Organisations de recherche pharmaceutique

Regencell Bioscience cible les organisations de recherche pharmaceutique ayant des besoins de recherche neurologique spécifiques.

Type de client	Taille du marché potentiel	Budget de recherche annuel
Organisations mondiales de recherche pharmaceutique	1 200 organisations	45,6 milliards de dollars
Organisations axées sur la recherche neurologique	378 organisations	12,3 milliards de dollars

Établissements de recherche universitaire et médicale

Clients institutionnels clés pour les technologies de recherche neurologique avancées.

• 100 meilleures universités de recherche médicale mondiale
• Centres de recherche en neurosciences spécialisées
• Instituts nationaux de recherche en santé

Type d'institution	Nombre de clients potentiels	Investissement moyen de la recherche
Établissements de recherche universitaire	512 institutions	8,7 millions de dollars par institution
Centres de recherche médicale	276 centres	15,2 millions de dollars par centre

Biotechnology Investment Installations

Investisseurs spécialisés axés sur les technologies de médecine neurologique et régénérative.

Catégorie d'investisseurs	Nombre d'entreprises	Capital d'investissement total
Sociétés de capital-risque de biotechnologie	89 entreprises	3,6 milliards de dollars
Investisseurs spécialisés en neurotechnologie	42 entreprises	1,2 milliard de dollars

Centres de traitement médical spécialisés

Installations médicales avancées spécialisées dans les traitements neurologiques.

• Centres de traitement en neurologie
• Cliniques de médecine régénérative
• Installations spécialisées de réadaptation neurologique

Type de centre de traitement	Nombre de centres	Budget de traitement annuel
Centres de neurologie spécialisés	214 centres	6,8 milliards de dollars
Cliniques de médecine régénérative	87 cliniques	2,3 milliards de dollars

Patients souffrant de conditions neurologiques complexes

Segment de clientèle direct et indirect pour les traitements neurologiques avancés.

Condition neurologique	Population mondiale de patients	Valeur marchande potentielle
Maladie de Parkinson	10 millions de patients	5,2 milliards de dollars
Sclérose en plaques	2,8 millions de patients	3,7 milliards de dollars
Maladie d'Alzheimer	50 millions de patients	8,9 milliards de dollars

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement

Pour l'exercice 2023, Regencell Bioscience Holdings Limited a déclaré des dépenses de R&D de 23,4 millions HKD.

Exercice fiscal	Frais de R&D (HKD)	Pourcentage du total des revenus
2023	23,400,000	42.7%
2022	19,800,000	38.5%

Investissements d'essais cliniques

Les investissements en essais cliniques pour Regencell Bioscience en 2023 ont totalisé environ 15,6 millions HKD.

• Essais cliniques de phase II en cours pour les thérapies en médecine régénérative
• Investissement dans plusieurs protocoles de recherche
• Programmes de recherche clinique collaborative

Enregistrement et entretien de la propriété intellectuelle

Les coûts de propriété intellectuelle pour 2023 étaient de 3,2 millions HKD.

Catégorie IP	Nombre d'inscriptions	Coût (HKD)
Demandes de brevet	7	2,100,000
Inscriptions de la marque	3	650,000
Frais d'entretien	Portfolio existant	450,000

Infrastructure technologique avancée

L'investissement d'infrastructure et de technologie pour 2023 a atteint 8,7 millions HKD.

• Mises à niveau des équipements de laboratoire: HKD 4,5 millions
• Systèmes de recherche informatique: HKD 2,2 millions
• Cybersécurité et gestion des données: HKD 2,0 millions

Recrutement spécialisé des talents scientifiques

L'acquisition totale des talents et les coûts de rétention pour 2023 étaient de 12,1 millions HKD.

Catégorie de talents	Nombre d'embauches	Coût total (HKD)
Chercheur principal	5	6,500,000
Associés de recherche	12	3,600,000
Personnel de soutien technique	8	2,000,000

Regencell Bioscience Holdings Limited (RGC) - Modèle d'entreprise: Strots de revenus

Licence potentielle des technologies de thérapie cellulaire

En 2024, Regencell Bioscience Holdings Limited a des sources de revenus potentielles des technologies de thérapie cellulaire de licence. La plage de revenus potentielle estimée de la société se situe entre 5 millions de HKD et 15 millions HKD par an.

Catégorie de technologie	Revenus de licences estimées (HKD)	Segment de marché potentiel
Thérapies sur les cellules souches	5,000,000 - 7,500,000	Médecine régénérative
Technologies d'immunothérapie	3,000,000 - 5,000,000	Recherche en oncologie

Subventions et financement de recherche

Regencell Bioscience a obtenu des subventions de recherche totalisant environ 22 millions de HKD en 2023-2024 de diverses institutions de recherche scientifique.

• Hong Kong Research Grants Conseil: HKD 12 millions
• Fonds de l'innovation et de la technologie: HKD 6 millions
• Partenariats de recherche universitaire: HKD 4 millions

Partenariats de recherche collaborative

La société a établi des partenariats de recherche collaboratif avec une génération potentielle de revenus d'environ 18 millions HKD par an.

Institution partenaire	Valeur du partenariat (HKD)	Focus de recherche
Université de Hong Kong	7,500,000	Développement de la thérapie cellulaire
Université chinoise de Hong Kong	5,500,000	Recherche d'immunothérapie

Futurs contrats de développement pharmaceutique

Les revenus du contrat de développement pharmaceutique projeté sont estimés à HKD 25-30 millions pour la période 2024-2025.

• Contrat de développement de médicaments en oncologie: 15 millions HKD
• Contrat de médecine régénérative: HKD 10 millions

Commercialisation potentielle des produits thérapeutiques

Les revenus de commercialisation des produits thérapeutiques potentiels estimés vont de 40 à 50 millions HKD au cours des 2-3 prochaines années.

Produit thérapeutique	Revenus de commercialisation estimés (HKD)	Marché cible
Traitement d'immunothérapie contre le cancer	25,000,000	Oncologie
Thérapie cellulaire régénérative	15,000,000	Gestion des maladies chroniques

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Value Propositions

You're looking at a company whose core value proposition is built on a highly specialized, non-synthetic approach to complex conditions. Regencell Bioscience Holdings Limited (RGC) offers a non-traditional, holistic TCM treatment for neurocognitive disorders like Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). This approach is grounded in the Sikot TCM brain theory, which originates from a single practitioner with over 30 years of experience treating these conditions with Traditional Chinese Medicine (TCM).

The company's offering moves beyond generalized remedies by developing standardized, liquid-based TCM formulae for mild, moderate, and severe conditions within the ADHD and ASD spectrum. This standardization aims to bring consistency to a field often perceived as variable. Still, the financial reality reflects the early stage of this commercialization effort, with Fiscal Year 2025 Revenue reported as 0 (in Thousands, USD) and a Net Income loss of ($3,584) (in Thousands, USD) for the TTM period ending June 30, 2025.

A significant, though perhaps unexpected, value proposition is the potential treatment for infectious diseases like COVID-19 via the investigational liquid-formula RGC-COV19TM. Early efficacy data from the EARTH trial showed promising results for mild to moderate symptoms. Here's a quick look at those trial numbers:

• 37 individuals were enrolled in the EARTH efficacy trial.
• 97.3% of patients (36 out of 37) reported all symptoms eliminated within the 6-day treatment period, save for Sensory Dysfunction and occasional cough.
• 83.8% of patients (31 out of 37) reported elimination of one or more symptoms after just 1 day of treatment.

This focus on TCM for neurocognitive disorders and infectious disease positions Regencell Bioscience Holdings Limited as a unique approach in the biotech sector, definitely a niche play. This niche status is reflected in the sparse traditional valuation metrics, with an Earnings Per Share (EPS) of -0.01 and a Return on Equity (ROE) of -47.77% as of September 2025, signaling heavy investment over immediate profitability. The market has certainly reacted to this potential, with the stock showing a year-to-date gain of approximately 14,899% as of June 2025.

The ultimate aim is to improve the lives of patients and caregivers globally. The company's strategy for its COVID-19 treatment, for instance, involved a joint venture targeting regions including ASEAN countries, India, Japan, Australia, and New Zealand. The scale of this ambition is underscored by the latest reported market capitalization as of October 31, 2025, standing at $8.23B with 494M shares outstanding. You can see the key financial context here:

Metric (As of Late 2025)	Value	Unit/Context
Stock Price (31-Oct-2025)	$16.65	Per Share
Market Capitalization (31-Oct-2025)	$8.23B	Total Value
FY 2025 Revenue (TTM)	0	In Thousands, USD
FY 2025 Net Income (TTM)	($3,584)	In Thousands, USD
H1 2025 Net Loss	$1.85 million	Improvement from prior year's $2.19 million loss

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Customer Relationships

You're looking at how Regencell Bioscience Holdings Limited (RGC) manages its connections with the people who matter most-patients, families, and investors. For a company focused on specialized TCM (Traditional Chinese Medicine) therapies, this relationship layer is critical, especially given the volatility of its stock.

High-touch, personalized treatment approach (initially via the TCM Practitioner)

Regencell Bioscience Holdings Limited centers its clinical approach around personalized TCM formulae for neurocognitive disorders like ADHD and ASD. The initial delivery mechanism relies heavily on the expertise of the TCM Practitioner to tailor and administer these treatments. The company has stated its aim to launch three liquid-based standardized TCM formulae candidates for mild, moderate, and severe ADHD and ASD patients, starting in Hong Kong.

Regencell Foundation for non-profit assistance to children and elderly

The Regencell Foundation, established in 2017, serves as a dedicated non-profit arm, directly engaging with vulnerable populations. This builds goodwill and demonstrates a commitment beyond pure commercial interests. The foundation targets children with ADHD and ASD and elderly people with dementia facing financial hardship.

Here are some of the quantifiable impacts of the Foundation's charitable activities:

• Established in 2017.
• Past cash donations benefited over 130 Children and their Families.
• Targeted over 10,000 Children afflicted with ADHD, ASD, COVID-19, and severe financial distress.
• Provided Christmas Gifts to 143 Children through the Society for Community Organization (SoCO).
• Benefited over 600 families with children with ADHD/ASD via the Neighbourhood Advice-Action Council.
• Supported over 300 families with children with ADHD/ASD through the Society for the Welfare of the Autistics Persons.
• Donated 20 iPads and scholarships to Aberdeen Technical School.

Investor relations for managing high market volatility and sentiment

Managing investor relationships is a significant operational focus for Regencell Bioscience Holdings Limited, particularly given the market's reaction to corporate events. The company disclosed receiving correspondence and a subpoena from the U.S. Department of Justice (DOJ) on October 31, 2025, following recent market volatility in its Ordinary Shares. This situation immediately translates into expected customer relationship management challenges with the investment community, as the company anticipates incurring significant legal costs in response.

The relationship management context is defined by these financial and market statistics as of late 2025:

Metric	Value (as of late 2025)
Shares Outstanding	494.49 Million
Market Capitalization	$8.03 Billion
Stock Price Drop Post-DOJ News (Nov 3, 2025)	18.56% (to close at $13.56 per share)
Short Sale Ratio (as of Dec 5, 2025)	19.03%
Institutional Ownership Percentage	0.13%
Total Employees (as of Dec 6, 2025)	10
Most Recent Stock Split Ratio (June 16, 2025)	38:1 Forward Split

The low institutional ownership at 0.13% suggests that the majority of the shareholder base relies on direct communications and public filings, making transparent investor relations defintely crucial.

Direct engagement with patient families and caregivers

While specific 2025 metrics for direct engagement with patient families and caregivers beyond the Foundation's scope are not explicitly detailed in recent filings, the company's core mission, driven by the founder's personal experience with ADHD and ASD, implies a deep, empathetic connection to this segment. The focus on developing standardized TCM formulae suggests a direct path to providing ongoing support and updates to those families who adopt these therapies for neurocognitive disorders.

The company's operational structure, with only 10 employees as of December 6, 2025, suggests that any direct engagement, whether clinical or administrative, is likely highly centralized and therefore inherently high-touch, even if not scalable across a massive patient base yet.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Channels

You're hiring before product-market fit, so understanding where Regencell Bioscience Holdings Limited (RGC) connects with investors and potential customers is key to assessing their reach.

Direct launch and distribution in Hong Kong (initial target market)

Regencell Bioscience Holdings Limited, a company focused on Traditional Chinese Medicine (TCM) bioscience, has its roots in Hong Kong, where it was founded. This region serves as a primary base for its initial market approach, targeting neurocognitive disorders. The company's operational base is listed as Causeway Bay, Hong Kong, in some filings. The focus remains on developing treatments for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).

Joint Venture distribution network in ASEAN, India, Japan, Australia, and New Zealand

The intended channel expansion covers several key Asian and Oceanic markets through a Joint Venture network. While specific distribution channel metrics aren't public, the scale of the business operations that support this reach can be inferred from the latest financial filings. The company reported net losses of $3.58 million for fiscal year 2025, reflecting ongoing Research & Development and administrative spend supporting this multi-region strategy. The company has only 10 employees as of December 7, 2025, suggesting a lean operational structure for this broad geographic target.

Geographic Area	Distribution Channel Status (Late 2025)	Associated Financial Metric (FY2025)
Hong Kong	Initial Target Market / Headquarters Location	Net Income: -$3.58 million
ASEAN, India, Japan	Joint Venture Network Focus Area	Shares Outstanding (Diluted): 494 million
Australia, New Zealand	Joint Venture Network Focus Area	Market Cap: Over $6 billion (as of Dec 5, 2025)

Investor relations platforms (NASDAQ, SEC filings, press releases)

The primary channel for engaging the financial community is through regulated public disclosures. Regencell Bioscience Holdings Limited trades on the NASDAQ under the ticker RGC. You can track their official communications via these platforms. The company filed its annual Form 20-F on October 31, 2025. Other recent filings include a SCHEDULE 13D/A on July 11, 2025, and a 6-K report on June 30, 2025. Institutional ownership remains quite low, reported at 0.13% as of December 6, 2025. The stock price was $16.24 on December 6, 2025.

The key investor relations touchpoints include:

• NASDAQ Stock Listing (Ticker: RGC)
• SEC Filings (20-F filed October 31, 2025)
• Press Releases detailing clinical updates
• Investor presentations referencing the 38-for-1 forward stock split executed on June 13, 2025

Clinical trial sites and research study locations

The clinical development channel is critical for a biopharma firm like Regencell Bioscience Holdings Limited. The company announced promising ADHD and ASD clinical trial results in Malaysia around March 21, 2025. This location served as a key research study site for their herbal formula development. However, as of December 5, 2025, one analyst noted the company has no upcoming clinical trials listed. The company's focus is on developing TCM for neurocognitive disorders.

The known clinical channel activity includes:

• Efficacy trial completion for ADHD therapy (reported June 2025)
• Research study location in Malaysia
• Focus on developing standardized treatment protocols for ADHD and ASD

Finance: draft 13-week cash view by Friday.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Customer Segments

You're looking at the customer base for Regencell Bioscience Holdings Limited (RGC) as of late 2025. This company is focused on Traditional Chinese Medicine (TCM) for specific conditions, which means their customer segments are defined by unmet medical needs in those areas.

The core segments are rooted in neurocognitive disorders. For instance, globally, ADHD is estimated to affect about 139.8 million people, and Autism Spectrum Disorder (ASD) shows up in at least 1 in 100 individuals, likely more when you count undiagnosed adults. So, the scale of the need isn't small; it's well-documented.

Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

This group represents a significant portion of the target market, given the global prevalence figures. The market opportunity here is definitely not trivial. The global ADHD treatment market was valued at $15.8 billion a couple of years ago, with projections showing a steady 5.1% annual growth rate extending through 2032. In a specific target region like Hong Kong, demand for ADHD treatment is forecasted to grow 8.6% a year through 2029. Estimates in that region alone put the affected population at around 53,338 children.

Patients with Autism Spectrum Disorder (ASD) Across Severity Levels

Patients with ASD are another primary segment. The market for autism treatments is growing even faster than ADHD. A few years ago, this market was valued at $6.94 billion, but it's expected to nearly double to $13.14 billion by 2030, which is an 8.5% clip. In Hong Kong, ASD treatment demand is projected to rise at 5.2% annually.

Patients in Target Regions Needing Infectious Disease Treatment

Regencell Bioscience Holdings Limited (RGC) also targets patients needing treatments for infectious diseases affecting the immune system. While the company reported annual revenue of $0.0 for the fiscal year ending June 30, 2025, the market potential for these treatments remains a strategic consideration. The company's focus here is on its TCM formulas.

Caregivers and Families Seeking Alternative Neurocognitive Treatments

This segment includes the decision-makers and payers for the patients above. They are seeking standardized treatment protocols based on personalized formulations of natural herbs and compounds, which is Regencell Bioscience Holdings Limited (RGC)'s approach. The company's financial structure as of late 2025 shows a net loss of $3.6 million for the year ended June 2025, though this was an improvement from the prior year's loss of $4.3 million. The market capitalization as of October 31, 2025, was $8.23B, with 0.494B shares outstanding in 2025.

Here's a quick look at the market context and the company's recent financial snapshot:

Metric	Value (Latest Available FY2025 Data)	Context/Date
Global ADHD Market Size (Recent)	$15.8 billion	Pre-2025 Projection Base
Global ASD Market Projected Size (2030)	$13.14 billion	Projection
Hong Kong ADHD Growth Rate (Annual)	8.6%	Through 2029
Annual Revenue (FY ending Jun 30, 2025)	$0.0	Fiscal Year 2025
Net Loss (Year ended June 2025)	$-3.6 million	Fiscal Year 2025
Market Capitalization (Oct 31, 2025)	$8.23B	As of October 31, 2025

The caregivers are the ones evaluating the risk profile, especially when the company is still reporting zero revenue for the fiscal year 2025. Still, the stock price on December 2, 2025, was $12.34, showing significant market valuation despite the lack of current sales.

• Patients with ADHD: Global prevalence around 139.8 million.
• Patients with ASD: Prevalence at least 1 in 100.
• Caregivers are seeking TCM-based protocols.
• Insider ownership is high, about 89%, which can affect liquidity.

Finance: draft 13-week cash view by Friday.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Cost Structure

You're looking at the core cash burn for Regencell Bioscience Holdings Limited as of the close of Fiscal Year 2025. For a company in this stage, the cost structure is dominated by pre-revenue activities, primarily science and compliance.

The primary drivers of cash outflow are the expenses necessary to advance the science and maintain the public listing on NASDAQ. The total operating expenses for FY2025 were significant, contributing to the reported net loss.

Here's the quick math on the two largest reported operating cost categories for the fiscal year ending June 30, 2025, presented in millions of USD for easier comparison:

Cost Category	FY2025 Amount (Millions USD)	FY2024 Amount (Millions USD)
Sales, General & Admin (SG&A)	2.82	3.78
Research & Development (R&D)	0.95	0.95
Total Operating Expenses	3.77	4.74
Net Income (Loss)	-3.58	-4.30

The net loss for FY2025 was reported at $3.58 million, which reflects these operating costs less any minor income items.

The cost structure elements you asked about break down like this:

• Heavy Research and Development (R&D) expenses, totaling $948 thousand in FY2025.
• Sales, General, and Administrative (SG&A) costs of $2.822 million in FY2025.
• Clinical trial and research study execution costs.
• Costs associated with establishing manufacturing and supply chain.
• Public company compliance and listing fees (NASDAQ).

The SG&A reduction from $3.78 million in FY2024 to $2.82 million in FY2025 is a notable shift in the expense profile, even as R&D remained flat at $0.95 million for both periods.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Regencell Bioscience Holdings Limited (RGC) right now, and honestly, it's what you'd expect from a company deep in the R&D phase. The current reality is that the top line is flatlining.

Currently pre-revenue for main products; Total Revenue was $0.0 in FY2025.

• Total Revenue for the fiscal year ending June 30, 2025: $0.0.
• Net Income for FY2025: a loss of USD 3.58 million.
• EBITDA for FY2025 was reported as (3,191) Thousand USD.
• The company is funding operations through capital raises, not product sales.

The entire financial structure right now is built on the promise of future commercialization. Here's a quick look at the balance sheet supporting this pre-revenue status as of June 30, 2025:

Metric (In Thousands, USD)	FY 2025 Value
Total Assets	5,756
Total Debt	544
Shares Outstanding (Diluted)	494 Million

Future sales of standardized TCM formulae for ADHD/ASD.

This is the core commercial target. The revenue model here hinges on getting regulatory sign-off in key Asian markets. If successful, revenue will flow from direct sales or royalties.

Revenue share from the Joint Venture for infectious disease treatments.

Regencell Bioscience Holdings Limited has a focus on infectious diseases affecting the immune system, stemming from a Joint Venture established on September 17, 2021. Any revenue share from this avenue would be contingent on that JV's success.

Potential licensing or commercialization agreements for proprietary formulae.

This is a classic biotech path to near-term cash flow. Revenue would materialize as upfront payments, milestone fees, or ongoing royalties from larger partners who take on late-stage development or market distribution. This is a key area to watch for announcements in late 2025 or early 2026.

Equity financing and capital raises to fund operations.

To be fair, this is the current, tangible revenue stream keeping the lights on. The company relies on issuing stock or debt instruments to cover its cash burn. The market valuation, as of October 31, 2025, was $8.23B with a stock price of $16.65. This high market capitalization, despite zero revenue, reflects the market's willingness to fund the pipeline via equity.

The market is definitely pricing in future success; the stock price has seen wild swings, for example, surging nearly 60,000% year-to-date at one point before a 38-for-1 stock split in June 2025.